Paraneoplastic syndromes associated with small cell lung cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 4, Issue 6, 2006, Pages 631-638

  Gandhi, Leena ^a   Johnson, Bruce E ^a,b  

^a Dana Farber Cancer Institute ^*

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Ectopic; Endocrine; Neurologic syndrome; Paraneoplastic; Small cell lung cancer

Indexed keywords

CANCER ANTIBODY; HU ANTIBODY;

ARTICLE; CANCER STAGING; CLINICAL FEATURE; CUSHING SYNDROME; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; ECTOPIC HORMONE PRODUCTION; HUMAN; HYPONATREMIA; LUNG SMALL CELL CANCER; OUTCOME ASSESSMENT; PARANEOPLASTIC SYNDROME; PROGNOSIS;

EID: 33747602338     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2006.0052     Document Type: Article

References (46)

1. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
2. Travis WD. Pathology of lung cancer. Clin Chest Med 2002;23: 65-81, viii.
3. Addis BJ. Neuroendocrine differentiation in lung carcinoma. Thorax 1995;50:113-115.
4. Jiang SX, Kameya T, Asamura H, et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004;17:222-229.
5. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003;349:1543-1554.
6. Brown WH. A case of pluriglandular syndrome: "diabetes of bearded women". Lancet 1928:1022-1023.
7. Ilias I, Torpy DJ, Pacak K, et al. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab 2005;90:4955-4962.
8. Liddle GW, Island DP, Ney RL, et al. Nonpituitary neoplasms and Cushing's syndrome. Ectopic "adrenocorticotropin" produced by nonpituitary neoplasms as a cause of Cushing's syndrome. Arch Intern Med 1963;111:471-475.
9. Terzolo M, Reimondo G, Ali A, et al. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol 2001; 12(suppl 2):S83-87.
10. Dimopoulos MA, Fernandez JF, Samaan NA, et al. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. Cancer 1992;69:66-71.
11. Sarlis NJ, Chanock SJ, Nieman LK. Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin. J Clin Endocrinol Metab 2000;85:42-47.
12. Jameson JL, Johnson BE. Paraneoplastic syndromes: endocrinologic/ hematologic. In: Kasper DL, Braunwald E, Fauci AS, et al. Harrison's Principles of Internal Medicine 16th ed. New York: McGraw Hill; 2006.
13. DeBold CR, Menefee JK, Nicholson WE, Orth DN. Proopiomelanocortin gene is expressed in many normal human tissues and in tumors not associated with ectopic adrenocorticotropin syndrome. Mol Endocrinol 1988;2:862-870.
14. Beuschlein F, Hammer GD. Ectopic pro-opiomelanocortin syndrome. Endocrinol Metab Clin North Am 2002;31:191-234.
15. Bates SE, Longo DL. Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 1987;14:102-138.
16. Shepherd FA, Laskey J, Evans WK, et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992;10:21-27.
17. Delisle L, Boyer MJ, Warr D, et al. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993;153:746-752.
18. Collichio FA, Woolf PD, Brower M. Management of patients with small cell carcinoma and the syndrome of ectopic corticotropin secretion. Cancer 1994;73:1361-1367.
19. Lin AY, Ihde DC. Recent developments in the treatment of lung cancer. JAMA 1992;267:1661-1664.
20. Sorensen JB, Andersen MK, Hansen HH. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med 1995;238:97-110.
21. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol 1986;4:1191-1198.
22. Bliss DP Jr, Battey JF, Linnoila RI, et al. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst 1990;82:305-310.
23. Kamoi K, Ebe T, Hasegawa A, et al. Hyponatremia in small cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer 1987;60:1089-1093.
24. Gross AJ, Steinberg SM, Reilly JG, et al. Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res 1993;53:67-74.
25. Campling BG, Sarda IR, Baer KA, et al. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer 1995; 75:2442-2451.
26. Johnson BE, Chute JP, Rushin J, et al. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156:1669-1678.
27. Chute JP, Taylor E, Williams J, et al. A metabolic study of patients with lung cancer and hyponatremia of malignancy. Clin Cancer Res 2006;12:888-896.
28. Lokich JJ. The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer 1982;50: 2111-2114.
29. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 1986; 46:4189-4194.
30. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;11(Pt 3): 577-596.
31. Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
32. Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999;353:117-118.
33. Wirtz PW, Lang B, Graus F, et al. P/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer. J Neuroimmunol 2005;164:161-165.
34. Dalmau J, Furneaux HM, Cordon-Cardo C, et al. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 1992; 141:881-886.
35. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998;50:652-657.
36. Mutoh T, Tachi M, Yano S, et al. Impairment of Trk-neurotrophin receptor by the serum of a patient with subacute sensory neuropathy. Arch Neurol 2005;62:1612-1615.
37. Byrne T, Mason WP, Posner JB, et al. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatry 1997;62:276-278.
38. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123(Pt 7):1481-1494.
39. Albert ML, Darnell JC, Bender A, et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat Med 1998; 4:1321-1324.
40. Polans AS, Witkowska D, Haley TL, et al. Recoverin, a photoreceptor-specific calcium-binding protein, is expressed by the tumor of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 1995;92:9176-9180.
41. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-1148.
42. Sillevis Smitt P, Grefkens J, de Leeuw B, et al. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002;249: 745-753.
43. Gill S, Murray N, Dalmau J, et al. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. Can J Neurol Sci 2003;30:269-271.
44. Graus F, Dalmou J, Rene R, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-2872.
45. Linke R, Schroeder M, Helmberger T, et al. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004;63:282-286.
46. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004;127:2331-2338.